<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0871-9721</journal-id>
<journal-title><![CDATA[Revista Portuguesa de Imunoalergologia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Port Imunoalergologia]]></abbrev-journal-title>
<issn>0871-9721</issn>
<publisher>
<publisher-name><![CDATA[Sociedade Portuguesa de Alergologia e Imunologia Clínica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0871-97212021000300209</article-id>
<article-id pub-id-type="doi">10.32932/rpia.2021.09.066</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Chronic respiratory failure in severe asthma - Questions answered after biological therapy, a clinical case]]></article-title>
<article-title xml:lang="pt"><![CDATA[Insuficiência respiratória crónica na asma grave - Respostas após terapêutica biológica, a propósito de um caso clínico]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Branco]]></surname>
<given-names><![CDATA[Joana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bom]]></surname>
<given-names><![CDATA[Filipa Todo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Furtado]]></surname>
<given-names><![CDATA[Sofia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Beatriz Ângelo Serviço de Pneumologia ]]></institution>
<addr-line><![CDATA[Loures ]]></addr-line>
<country>Portugal</country>
</aff>
<pub-date pub-type="pub">
<day>30</day>
<month>09</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>09</month>
<year>2021</year>
</pub-date>
<volume>29</volume>
<numero>3</numero>
<fpage>209</fpage>
<lpage>213</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S0871-97212021000300209&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S0871-97212021000300209&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S0871-97212021000300209&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Severe asthma is defined as either refractory to traditional therapies or controlled only with therapies that have intolerable side effects. Biological agents are known to offer treatment alternatives to patients with type 2 inflammation severe asthma. We describe the case of a woman with a long history of type 2 inflammation severe asthma, with uncontrolled symptoms and need of systemic corticosteroid therapy as prevailing features, and with respiratory failure that differentiated her from other patients with severe asthma.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO A asma grave é definida como sendo refratária à terapêutica máxima otimizada ou que é apenas controlada por terapêutica com efeitos secundários não toleráveis. Os agentes biológicos constituem alternativas em doentes com asma grave com inflamação tipo 2. Descrevemos o caso de uma doente com asma grave com inflamação tipo 2 de longa evolução, em que predominavam a ausência de controlo de sintomas e a necessidade de corticoterapia sistémica e concomitantemente insuficiência respiratória crónica característica diferenciadora relativamente a outros casos de asma grave.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Chronic respiratory failure]]></kwd>
<kwd lng="en"><![CDATA[mepolizumab]]></kwd>
<kwd lng="en"><![CDATA[severe asthma]]></kwd>
<kwd lng="pt"><![CDATA[Asma grave]]></kwd>
<kwd lng="pt"><![CDATA[insuficiência respiratória crónica]]></kwd>
<kwd lng="pt"><![CDATA[mepolizumab]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Casale]]></surname>
<given-names><![CDATA[TB]]></given-names>
</name>
<name>
<surname><![CDATA[Cardet]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biological therapies for eosinophilic asthma]]></article-title>
<source><![CDATA[Expert Opin Biol Ther]]></source>
<year>2018</year>
<volume>18</volume>
<page-range>747-54</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Global Strategy for Asthma Management and Prevention]]></article-title>
<source><![CDATA[GINA Report]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pavord]]></surname>
<given-names><![CDATA[ID]]></given-names>
</name>
<name>
<surname><![CDATA[Korn]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Howarth]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bleeckers]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
<name>
<surname><![CDATA[Buhl]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Keene]]></surname>
<given-names><![CDATA[ON]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double&#8209;blind, placebo&#8209;controlled trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2012</year>
<volume>380</volume>
<page-range>651-9</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barbosa]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Magalhães]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Sousa]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Azevedo]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
<name>
<surname><![CDATA[Fonseca]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost of asthma in Portuguese adults: A population&#8209;based, cost&#8209;of&#8209;illness study]]></article-title>
<source><![CDATA[Rev Port Pneumologia]]></source>
<year>2017</year>
<volume>23</volume>
<page-range>323&#8209;330</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caramori]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Fabbri]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Paioli]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Falcone]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Severino]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Felisatti]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Asthma is not a common cause of severe chronic respiratory failure in non&#8209;smokers: ALOT study]]></article-title>
<source><![CDATA[Monaldi Arch Chest Dis]]></source>
<year>2005</year>
<volume>63</volume>
<page-range>84&#8209;87</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Fu]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pulmonary Embolism and Severe Asthma: Case Report and Literature Review]]></article-title>
<source><![CDATA[Medicina]]></source>
<year>2019</year>
<volume>55</volume>
<page-range>647</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hambly]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Nair]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Monoclonal antibodies for the treatment of refractory asthma]]></article-title>
<source><![CDATA[Curr Opin Pulm Med]]></source>
<year>2014</year>
<volume>20</volume>
<page-range>87-94</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giannetti]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Cardet]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interleukin&#8209;5 antagonists usher in a new generation of asthma therapy]]></article-title>
<source><![CDATA[Curr Allergy Asthma Rep]]></source>
<year>2016</year>
<volume>16</volume>
<page-range>80</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mukherjee]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sehmi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Nair]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti&#8209;IL5 therapy for asthma and beyond]]></article-title>
<source><![CDATA[World Allergy Organ J]]></source>
<year>2014</year>
<volume>7</volume>
<page-range>32</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bel]]></surname>
<given-names><![CDATA[EH]]></given-names>
</name>
<name>
<surname><![CDATA[Wenzel]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Prazma]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Keene]]></surname>
<given-names><![CDATA[ON]]></given-names>
</name>
<name>
<surname><![CDATA[Yancey]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral glucocorticoid&#8209;sparing effect of mepolizumab in eosinophilic asthma]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2014</year>
<volume>371</volume>
<page-range>1189&#8209;97</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
